Well tolerated at all doses with no safety signals 100% seroconversion at highest dose after two of the three planned vaccinations Dose-dependent antibody responses against CMV gB antigen Full data after third dose expected first half of 2018 Conference Call...
Read More
Cytomegalovirus (“CMV”), a common virus that infects over half of adults by age 40, may cause changes in normal-weight women that could increase the risk of metabolic syndrome says new research led by investigators at the University of California, San Francisco...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) today provided an update on its cytomegalovirus (“CMV”) Phase I clinical study, which is assessing the safety and tolerability of VBI’s vaccine candidate to prevent congenital CMV infection. Congenital CMV infection is...
Read More
Cytomegalovirus (“CMV”) is a common virus that infects one in every two people in many developed countries. Most CMV infections are “silent,” meaning most people who are infected with CMV exhibit no signs or symptoms. However, CMV can cause serious...
Read More
Acute lymphocytic leukemia (“ALL”), also known as acute lymphoblastic leukemia, is a cancer of the blood and bone marrow, predominantly seen in children between the ages of two and five. ALL is the most common type of childhood cancer in...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) today announced that it has completed enrollment and initial dosing of all participants in the Phase I clinical study to evaluate its preventative cytomegalovirus (“CMV”) vaccine candidate. The Phase I study is...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) is scheduled to present at the 10th Vaccine Congress on Monday, September 5, 2016 at 12:45 PM CEST (6:45 AM ET). The event is being held at the NH Grand Hotel Krasnapolsky...
Read More
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) today announced that, following a review of safety data from the limited safety immunization period, the Data Safety Monitoring Board (“DSMB”) has no objection to VBI continuing with the enrollment of participants...
Read More
Alzheimer’s disease (“AD”) is the most common cause of dementia in developed countries and is one of the leading sources of morbidity and mortality in aging populations. Clinical manifestations of AD include memory impairment, decline in executive function, and impaired...
Read More